Business Context and Reporting Period
Company: Biodesix, Inc. (BDSX)
Filing Type: Form 8-K (Current Report)
Date of Report: September 26, 2025
Reporting Period: Event date September 26, 2025; Signed October 1, 2025
Context: The filing addresses the Company's compliance status with Nasdaq listing requirements.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Regulatory Status Change: Biodesix, Inc. regained compliance with the Nasdaq Listing Rule 5450(a)(1) Minimum Bid Price Requirement.
- Previous Non-Compliance: On March 24, 2025, the Company was notified of non-compliance because its common stock closed below $1.00 per share for 30 consecutive business days.
- Resolution Criteria Met: The Company successfully maintained a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days.
- Current Status: Nasdaq confirmed the matter is closed as of September 26, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the receipt of a letter from the Nasdaq Listing Qualifications Department stating compliance has been regained. No forward-looking guidance, financial outlook, or new risk factors are disclosed in this specific report.
Unusual Items: None reported beyond the resolution of the prior listing deficiency.
Investor Verification Checklist
- Verify the current trading price of BDSX to ensure it remains above the $1.00 threshold to avoid future non-compliance notices.
- Review the Company's most recent 10-Q or 10-K for financial health metrics, as this 8-K contains no financial data.
- Confirm the stock's trading volume and liquidity on The Nasdaq Global Market following the compliance restoration.